(Q39296299)

10 September 2017

title

How can an effective drug to treat irritable bowel syndrome be successfully developed? (English)

1 reference

10 September 2017

main subject

irritable bowel syndrome

1 reference

M Duracinsky

1

1 reference

10 September 2017

O Chassany

series ordinal

2

1 reference

10 September 2017

language of work or name

French

0 references

publication date

1 February 2009

1 reference

Gastroenterologie Clinique et Biologique

10 September 2017

published in

1 reference

10 September 2017

volume

33 Suppl 1

1 reference

10 September 2017

page(s)

S26-34

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

10 September 2017

1 reference

7 January 2021

The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

Mechanisms of hypersensitivity in IBS and functional disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

Postinfectious irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

Review article: the overlap between functional dyspepsia and irritable bowel syndrome -- a tale of one or two disorders?

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

Functional bowel disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

Diagnostic criteria for irritable bowel syndrome: utility and applicability in clinical practice.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

Durability of the diagnosis of irritable bowel syndrome based on clinical criteria.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

Challenges in drug development for functional gastrointestinal disorders. Part II: visceral pain

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

Symptom severity but not psychopathology predicts visceral hypersensitivity in irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

Relationship between symptoms and hypersensitivity to rectal distension in patients with irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

Relationship between rectal sensitivity, symptoms intensity and quality of life in patients with irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

Is visceral hypersensitivity correlated with symptom severity in children with functional gastrointestinal disorders?

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

Contributions of pain sensitivity and colonic motility to IBS symptom severity and predominant bowel habits

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

The placebo effect in irritable bowel syndrome trials: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

Defining the predictors of the placebo response in irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

Design of treatment trials for functional gastrointestinal disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

Bowel habit subtypes and temporal patterns in irritable bowel syndrome: systematic review.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

Characterization of the alternating bowel habit subtype in patients with irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

Stability of irritable bowel syndrome using a Rome II-based classification

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

Predictive factors of irritable bowel syndrome improvement: 1-year prospective evaluation in 400 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

Reports of "satisfactory relief" by IBS patients receiving usual medical care are confounded by baseline symptom severity and do not accurately reflect symptom improvement

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

Probiotics and the irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

Effect of baseline symptom severity on patient-reported outcomes in gastroesophageal reflux disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

Do psychosocial factors define symptom severity and patient status in irritable bowel syndrome?

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

Acute exacerbation of pain in irritable bowel syndrome: efficacy of phloroglucinol/trimethylphloroglucinol. A randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

Uncomfortable implications: placebo equivalence in drug management of a functional illness

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

Characteristics of patients with irritable bowel syndrome recruited from three sources: implications for clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

Irritable bowel syndrome: the burden and unmet needs in Europe

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

Is amitriptyline really effective in diarrhoea-predominant irritable bowel syndrome?

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

Meta-analysis of the effects of ipratropium bromide in adults with acute asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

Discrepancies between patient-reported outcomes and clinician-reported outcomes in chronic venous disease, irritable bowel syndrome, and peripheral arterial occlusive disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

Measuring successful treatment of irritable bowel syndrome: is "satisfactory relief " enough?

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

Stability of the patient acceptable symptomatic state over time in outcome criteria in ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

Validation of a specific quality of life questionnaire for functional digestive disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

Systematic review: the efficacy of treatments for irritable bowel syndrome--a European perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2971522-2

7 January 2021

10.1016/S0399-8320(09)71522-2

Identifiers

DOI

1 reference

10 September 2017

1 reference